Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMI1 | P35226 | 14/20 | 0.55 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | LYN | P07948 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | HCK | P08631 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16540632 | 0.92 | BMI1 (0.54) | BMI1KCNH3PIK3CAMTORIDH2 | |
| SCHEMBL16540495 | 0.87 | BMI1 (0.72) | BMI1KCNH3PIK3CAMTORIDH2 | |
| Bromide SCHEMBL16541096 | 0.86 | BMI1 (0.71) | BMI1KCNH3PIK3CAMTORIDH2 | |
| Hydrochloric Acid SCHEMBL16540949 | 0.86 | BMI1 (0.71) | BMI1KCNH3PIK3CAMTORLCK | |
| SCHEMBL17938207 | 0.84 | BMI1 (0.58) | BMI1PIK3CAMTORLCKLYN | |
| SCHEMBL16540998 | 0.84 | BMI1 (0.55) | BMI1KCNH3PIK3CAMTORIDH2 | |
| SCHEMBL16540549 | 0.84 | BMI1 (0.74) | BMI1PIK3CAMTORLCKLYN | |
| SCHEMBL15747673 | 0.82 | BMI1 (0.55) | BMI1KCNH3PIK3CAMTORLCK | |
| SCHEMBL17938229 | 0.82 | BMI1 (0.59) | BMI1PIK3CAMTORKCNH2SCN9A | |
| Sulfuric Acid SCHEMBL16540914 | 0.82 | BMI1 (0.65) | BMI1KCNH3PIK3CAMTORLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3039015-B1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2019-10-30 | — | — | EP | claimed |
| US-10370371-B2 | Substituted pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | claimed |
| US-20160214978-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-07-28 | — | — | US | claimed |
| EP-3039015-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2016-07-06 | — | — | EP | claimed |
| WO-2015030847-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | WO | claimed |
| EP-3039015-B1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3039015-B1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10370371-B2 | Substituted pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370371-B2 | Substituted pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20160214978-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214978-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214978-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| EP-3039015-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015030847-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370371-B2 | Substituted pyrimidine Bmi-1 inhibitors | BMI1, BAZ2A, BRPF3 | BMI1 1/4885KCNH3 4224/4885PIK3CA 1968/4885 |
| US-20160214978-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | BMI1, BAZ2A, BRPF3 | BMI1 1/4885KCNH3 4224/4885PIK3CA 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.